EPINEPHRINE

Question 0

MECHANISM OF ACTION

Answer 0

A1 AGONIST—-SECOND MESSENGER RELEASE OF CALCIUM IN VSMC—-PERIPHERAL VASOCONSTRICTION—– INCREASED SVR–INCREASED BP
B1 AGONIST—–INCREASED INTRACELLULAR CA2IN CARDIAC CELLS- POSITIVE INOTROPY. CHRONOTROPY DROMOTROPY
B2 AGONIST BRONCHIAL SMOOTH MUSCLE RELAXATION— BRONCHODILATION BLOCKS RELEASE OF CALCIUM IN AN SUBSEQUENT DESTRUCTION OF MAST CELLS

Question 1

DRUG CLASSIFICATION

Answer 1

SYMPATHOMIMETIC/SYMPATHETIC AGONIST/ CATECHOLAMINE

Question 2

ONSET OF ACTION?

Answer 2

<2 MINUETS IV 3-10 MINUTES IM

Question 3

PEAK EFFECTS

Answer 3

<5 MINUTES IV, 20MINUTES IM

Question 4

DURATION OF EFFECT

Answer 4

5-10 IV 20-30 IM

Question 5

HALF LIFE

Answer 5

5 MINUTES IV

Question 6

INDICATIONS FIELD USE?

Answer 6

CARDIAC ARREST
ANAPHYLAXIS/SEVERE REACTIVE AIRWAY DISEASE/ASTHMA
SYMPTOMATIC BRADYCDIA/HYPOTENSION

Question 7

CONTRINDICATIONS

Answer 7

TACHYDYSRHYTHMIAS

Question 8

SIDE EFFECTS / ADVERSE REACTIONS

Answer 8

ANXIETY HA DYSRHYTHMIAS TREMULOUSNESS DIZZINESS N+V

Question 9

DOSE CARDIAC ARREST

Answer 9

ADULT 0.5-1MG RAPID IV, IO (1:10,000) Q 3-5 MIN

PEDI 0.01 MG/KG (1:10,000) RAPID IV, IO Q 3-5 MIN

Question 10

DOSE ANAPHYLAXIS/ASTHMA

Answer 10

ADULT 0.3-0.5 MG (1:1000) IM

PEDI 0.01 MG/KG (1:1000) IM MAX 0.3MG THEN 0.01 MG/KG 1:10,000 SLOW IV,IO

Question 11

PRECAUTIONS

Answer 11

SHOULD BE PROTECTED FROM LIGHT
CAUTION WITH CAD AND PREGNANCY

LEADS TO INCREASE IN MYOCARDIAL OXYGEN DEMAND

Question 12

DRUG-DRUG INTERACTIONS

Answer 12

PH DEPENDENT DEACTIVATED BY ALKALINE SOLUTIONS; EFFECTS INTENSIFIED WITH PT’S TAKING ANTIDEPRESSANTS, REACTS WITH CACL2 AND NAHCO3 TO FORM PPT IN IV TUBING.